Dual-targeting biomimetic delivery for anti-glioma activityviaremodeling the tumor microenvironment and directing macrophage-mediated immunotherapy

Abstract

A dual-targeting biomimetic codelivery and treatment strategy was developed for anti-glioma activity.

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

“…Realizing the great importance of element iron in malignancy suppression, Zanganeh et al employed ferumoxytol, one FDA‐approved iron oxide nanoparticle, promoted macrophage recruitment and transferred toward M1 phenotypes, creating an autocrine feedback loop to maintain the generation of TNF‐α and NO to induce tumor cell apoptosis . A macrophage modulator, regorafenib, was also encapsulated in mannose‐functionalized albumin nanoparticles to target pro‐tumor M2 phenotype macrophages and switch to M1 macrophages . A similar strategy has been utilized to modify the upconversion nanocrystals with hyaluronic acid (HA), a natural glycosaminoglycan, which reeducate successfully pro‐tumor M2 to antitumor M1 macrophages .…”

Roles of Albumin‐Binding Proteins in Cancer Progression and Biomimetic Targeted Drug Delivery

“…This system,w ith codelivery of disulfiram/copper complex and regorafenib, could remodel the glioma immune microenvironment by repolarizing TAMf rom protumor M2 to antitumor M1 phenotype,s uppressing the Treg, and activating the CD8 + Tc ells. [65] In another study,i t was reported that SPARC and mannose receptor( CD206) were simultaneously overexpressed in TAM2 and drug-resistant colon cancer cells. Therefore, am annosylated albuminN Pw as developed for dual targeting to SPARC and CD206a nd dual delivery to both TAM2 and colon cancer cells;as o-called "two birds with one stone" strategy.…”

“…In addition, this system took advantage of the overexpression of SPARC and mannose receptors on TAM2; thus also targeting the protumor TAM2. This system, with codelivery of disulfiram/copper complex and regorafenib, could remodel the glioma immune microenvironment by repolarizing TAM from protumor M2 to antitumor M1 phenotype, suppressing the Treg, and activating the CD8 + T cells . In another study, it was reported that SPARC and mannose receptor (CD206) were simultaneously overexpressed in TAM2 and drug‐resistant colon cancer cells.…”

“…Am ild albumin denaturation method with urea/NaBH 4 hasb een recently reported forp reparing albuminN Ps through hydrophobic druginduced self-assembly ( Figure 5), by whichs everala lbuminbased codelivery systemsw ere developed to co-encapsulate 4-HPR/PTX for glioma-targeting therapy, or the combination of disulfiram/copper complex and regorafenib for colonc ancer and glioma therapy. [3b, 29,65] It was reported that the BBB in gliomaa reas overexpressed ABP (e.g.,g p60 andS PARC), which potentially served as the delivery target for albumin NPs. In addition, SPARCw as also overexpressed in gliomac ells;h owever,m inor expression of ABP was found in normalb rain tissues.…”

“…SPARC was also found with overexpression in the M2-phenotype tumor-associated macrophage (TAM2), therebys erving as ac ommon target for both glioma vessel epithelium, glioma cells, and TAMs. [65] The albumin NPs, which were modified with aT fR-binding peptide T12 and mannose, could pass the BBB through nutrient transporters (i.e.,T fR and the albumin-binding receptor SPARC) that were both overexpressed in the BBB and glioma cells;t hus achieving biomimeticd elivery to glioma. In addition, this system took advantage of the overexpression of SPARC and mannoser eceptors on TAM2;t hus also targetingt he protumor TAM2.…”